Cookie Policy: This site uses cookies to improve your experience. You can find out more about our use of cookies in our Privacy Policy. By continuing to browse this site you agree to our use of cookies.
AdipoGen Life Sciences
R-848
70
CHF
CHF 70.00
In stock
AG-CR1-3582-M0055 mgCHF 70.00
AG-CR1-3582-M02525 mgCHF 280.00
| Product Details | |
|---|---|
| Synonyms | Resiquimod; S 28463; R848 |
| Product Type | Chemical |
| Properties | |
| Formula |
C17H22N4O2 |
| MW | 314.4 |
| CAS | 144875-48-9 |
| Source/Host Chemicals | Synthetic. |
| Purity Chemicals | ≥98% |
| Appearance | White to off-white powder. |
| Solubility | Soluble in DMSO, dichloromethane or methanol. Slightly soluble in acetonitrile or ethyl acetate. |
| InChi Key | BXNMTOQRYBFHNZ-DZQCGVKKCS |
| Smiles | CCOCC1=NC2=C(N1CC(C)(C)O)C1=C(C=CC=C1)N=C2N |
| Shipping and Handling | |
| Shipping | AMBIENT |
| Short Term Storage | +4°C |
| Long Term Storage | -20°C |
| Handling Advice |
After reconstitution, prepare aliquots and store at -20°C. Avoid freeze/thaw cycles. |
| Use/Stability |
Stable for at least 2 years after receipt when stored at -20°C. Stock solutions are stable for at least 3 months when stored at -20°C. |
| Documents | |
| MSDS |
 Download PDF |
| Product Specification Sheet | |
| Datasheet |
Download PDF |
Description
- Immune response modifier. Potent antitumor and antiviral compound [1, 3, 10, 11, 13, -16].
- Stimulates antibody secretion and cytokine production [2].
- Used as adjuvant to increase the effectiveness of vaccines [2, 7, 9, 10].
- Potent and selective synthetic ligand for Toll-like receptor 7 (TLR7) in mouse and for TLR7 and TLR8 in human [4-6].
- Activates immune cells via the TLR7/TLR8 MyD88-dependent signaling pathway and leads to the induction of NF-κB [4].
- NLRP3/NALP3 inflammasome activator, independent of TLRs and RIG-I [8].
- Upregulator of the opioid growth factor receptor [12].
- Used in the treatment of skin lesions such as herpes simplex virus [16].
Product References
- Modulation of TH1 and TH2 cytokine production with the immune response modifiers, R-848 and imiquimod: T.L. Wagner, et al.; Cell Immunol. 191, 10 (1999)
- Adjuvant activities of immune response modifier R-848: comparison with CpG ODN: J.P. Vasilakos, et al.; Cell Immunol. 204, 64 (2000)
- The immune response modifier resiquimod mimics CD40-induced B cell activation: G.A. Bishop, et al.; Cell. Immunol. 208, 9 (2001)
- Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway: H. Hemmi, et al.; Nat. Immunol. 3, 196 (2002)
- Human TLR7 or TLR8 independently confer responsiveness to the antiviral compound R-848: M. Jurk, et al.; Nat. Immunol. 3, 499 (2002)
- Synthetic TLR agonists reveal functional differences between human TLR7 and TLR8: K.B. Gorden, et al.; J. Immunol. 174, 1259 (2005)
- TLR agonists as vaccine adjuvants: comparison of CpG ODN and Resiquimod (R-848): R.D. Weeratna, et al.; Vaccine 23, 5263 (2005)
- Bacterial RNA and small antiviral compounds activate caspase-1 through cryopyrin/Nalp3: T.D. Kanneganti, et al.; Nature 440, 233 (2006)
- Additive effects of CpG ODN and R-848 as adjuvants on augmenting immune responses to HBsAg vaccination: R. Ma, et al.; BBRC 361, 537 (2007)
- Resiquimod and other immune response modifiers as vaccine adjuvants: M.A. Tomai, et al.; Expert Rev. Vaccines 6, 835 (2007) (Review)
- The antiviral activity of Toll-like receptor 7 and 7/8 agonists: R.L. Miller, et al.; Drug News Perspect. 21, 69 (2008) (Review)
- Imiquimod upregulates the opioid growth factor receptor to inhibit cell proliferation independent of immune function: I.S. Zagon, et al.; Exp. Biol. Med. 233, 968 (2008)
- Targeting Toll-like receptor 7/8 enhances uptake of apoptotic leukemic cells by monocyte-derived dendritic cells but interferes with subsequent cytokine-induced maturation: W. van den Ancker, et al.; Cancer Immunol. Immunother. 60, 37 (2011)
- Treatment with the TLR7 agonist R848 induces regulatory T-cell-mediated suppression of established asthma symptoms: L.P. Van, et al.; Eur. J. Immunol. 41, 1992 (2011)
- R-848 triggers the expression of TLR7/8 and suppresses HIV replication in monocytes: H. Nian, et al.; BMC Infect. Dis. 12, 5 (2012)
- Resiquimod|a topical drug for viral skin lesions and skin cancer: T. Meyer, et al.; Expert Opin. Investig. Drugs 22, 149 (2013)
- TLR7 agonists display potent antiviral effects against norovirus infection via innate stimulation: D.E. Tuipulotu, et al.; Antimicrob. Agents Chemother. 62, e02417 (2018)
- Systemic and intestinal porcine epidemic diarrhea virus-specific antibody response and distribution of antibody-secreting cells in experimentally infected conventional pigs: Vet. Res. 52, 2 (2021)
Related Products
